Citius Oncology prices $9 million offering; shares down over 5%
Source: SeekingAlpha
2025-09-09 08:42:16 ET
More on Citius Pharmaceuticals, Citius Oncology
- Citius Oncology: Is A Lymphir Launch Coming Too Late?
- Citius Oncology announces pricing of $9 million public offering
- Cencora distribution deal boosts Citius shares
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Citius Oncology prices $9 million offering; shares down over 5%
Citius Pharmaceuticals Inc.
NASDAQ: CTXR
CTXR Trading
-4.91% G/L:
$0.8549 Last:
276,381 Volume:
$0.895 Open:
CTXR Latest News
March 10, 2026 08:47:00 am
Citius Oncology Announces Positive Topline Results from Investigator?Initiated Phase 1 Study of LYMPHIR(TM) in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
February 24, 2026 08:00:00 am
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
February 13, 2026 03:01:28 pm
Citius Pharmaceuticals Reports First Revenue Following LYMPHIR(TM) Launch
February 13, 2026 08:00:00 am
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
CTXR Stock Data
$17,182,352
18,541,285
0.66%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
Cranford
